Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease

Charles H. Vite, Jessica H. Bagel, Gary P. Swain, Maria Prociuk, Tracey U. Sikora, Veronika M. Stein, Patricia O'Donnell, Therese Ruane, Sarah Ward, Alexandra Crooks, Su Li, Elizabeth Mauldin, Susan Stellar, Marc De Meulder, Mark L. Kao, Daniel S. Ory, Cristin Davidson, Marie T. Vanier, Steven U. Walkley

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Niemann-Pick type C1 (NPC) disease is a lysosomal storage disease caused by mutations in the NPC1 gene, leading to an increase in unesterified cholesterol and several sphingolipids, and resulting in hepatic disease and progressive neurological disease. We show that subcutaneous administration of the pharmaceutical excipient 2-hydroxypropyl-β-cyclodextrin (HPbCD) to cats with NPC disease ameliorated hepatic disease, but doses sufficient to reduce neurological disease resulted in pulmonary toxicity. However, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near-normal concentrations of cholesterol and sphingolipids. Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides. An increase in hearing threshold was identified as a potential adverse effect. These studies in a feline animal model have provided critical data on efficacy and safety of drug administration directly into the central nervous system that will be important for advancing HPβCD into clinical trials.

Original languageEnglish (US)
Article number276ra26
JournalScience Translational Medicine
Volume7
Issue number276
DOIs
StatePublished - Feb 25 2015

Fingerprint

Type C Niemann-Pick Disease
Cerebellar Diseases
Purkinje Cells
Felidae
Cyclodextrins
Cell Death
Sphingolipids
Cats
Cholesterol
Cisterna Magna
Lysosomal Storage Diseases
Gangliosides
Excipients
Liver
Pharmaceutical Preparations
Hearing
Disease Progression
Central Nervous System
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. / Vite, Charles H.; Bagel, Jessica H.; Swain, Gary P.; Prociuk, Maria; Sikora, Tracey U.; Stein, Veronika M.; O'Donnell, Patricia; Ruane, Therese; Ward, Sarah; Crooks, Alexandra; Li, Su; Mauldin, Elizabeth; Stellar, Susan; De Meulder, Marc; Kao, Mark L.; Ory, Daniel S.; Davidson, Cristin; Vanier, Marie T.; Walkley, Steven U.

In: Science Translational Medicine, Vol. 7, No. 276, 276ra26, 25.02.2015.

Research output: Contribution to journalArticle

Vite, CH, Bagel, JH, Swain, GP, Prociuk, M, Sikora, TU, Stein, VM, O'Donnell, P, Ruane, T, Ward, S, Crooks, A, Li, S, Mauldin, E, Stellar, S, De Meulder, M, Kao, ML, Ory, DS, Davidson, C, Vanier, MT & Walkley, SU 2015, 'Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease', Science Translational Medicine, vol. 7, no. 276, 276ra26. https://doi.org/10.1126/scitranslmed.3010101
Vite, Charles H. ; Bagel, Jessica H. ; Swain, Gary P. ; Prociuk, Maria ; Sikora, Tracey U. ; Stein, Veronika M. ; O'Donnell, Patricia ; Ruane, Therese ; Ward, Sarah ; Crooks, Alexandra ; Li, Su ; Mauldin, Elizabeth ; Stellar, Susan ; De Meulder, Marc ; Kao, Mark L. ; Ory, Daniel S. ; Davidson, Cristin ; Vanier, Marie T. ; Walkley, Steven U. / Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. In: Science Translational Medicine. 2015 ; Vol. 7, No. 276.
@article{af37098fbdc64a61a3f668969e985f93,
title = "Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease",
abstract = "Niemann-Pick type C1 (NPC) disease is a lysosomal storage disease caused by mutations in the NPC1 gene, leading to an increase in unesterified cholesterol and several sphingolipids, and resulting in hepatic disease and progressive neurological disease. We show that subcutaneous administration of the pharmaceutical excipient 2-hydroxypropyl-β-cyclodextrin (HPbCD) to cats with NPC disease ameliorated hepatic disease, but doses sufficient to reduce neurological disease resulted in pulmonary toxicity. However, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near-normal concentrations of cholesterol and sphingolipids. Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides. An increase in hearing threshold was identified as a potential adverse effect. These studies in a feline animal model have provided critical data on efficacy and safety of drug administration directly into the central nervous system that will be important for advancing HPβCD into clinical trials.",
author = "Vite, {Charles H.} and Bagel, {Jessica H.} and Swain, {Gary P.} and Maria Prociuk and Sikora, {Tracey U.} and Stein, {Veronika M.} and Patricia O'Donnell and Therese Ruane and Sarah Ward and Alexandra Crooks and Su Li and Elizabeth Mauldin and Susan Stellar and {De Meulder}, Marc and Kao, {Mark L.} and Ory, {Daniel S.} and Cristin Davidson and Vanier, {Marie T.} and Walkley, {Steven U.}",
year = "2015",
month = "2",
day = "25",
doi = "10.1126/scitranslmed.3010101",
language = "English (US)",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "276",

}

TY - JOUR

T1 - Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease

AU - Vite, Charles H.

AU - Bagel, Jessica H.

AU - Swain, Gary P.

AU - Prociuk, Maria

AU - Sikora, Tracey U.

AU - Stein, Veronika M.

AU - O'Donnell, Patricia

AU - Ruane, Therese

AU - Ward, Sarah

AU - Crooks, Alexandra

AU - Li, Su

AU - Mauldin, Elizabeth

AU - Stellar, Susan

AU - De Meulder, Marc

AU - Kao, Mark L.

AU - Ory, Daniel S.

AU - Davidson, Cristin

AU - Vanier, Marie T.

AU - Walkley, Steven U.

PY - 2015/2/25

Y1 - 2015/2/25

N2 - Niemann-Pick type C1 (NPC) disease is a lysosomal storage disease caused by mutations in the NPC1 gene, leading to an increase in unesterified cholesterol and several sphingolipids, and resulting in hepatic disease and progressive neurological disease. We show that subcutaneous administration of the pharmaceutical excipient 2-hydroxypropyl-β-cyclodextrin (HPbCD) to cats with NPC disease ameliorated hepatic disease, but doses sufficient to reduce neurological disease resulted in pulmonary toxicity. However, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near-normal concentrations of cholesterol and sphingolipids. Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides. An increase in hearing threshold was identified as a potential adverse effect. These studies in a feline animal model have provided critical data on efficacy and safety of drug administration directly into the central nervous system that will be important for advancing HPβCD into clinical trials.

AB - Niemann-Pick type C1 (NPC) disease is a lysosomal storage disease caused by mutations in the NPC1 gene, leading to an increase in unesterified cholesterol and several sphingolipids, and resulting in hepatic disease and progressive neurological disease. We show that subcutaneous administration of the pharmaceutical excipient 2-hydroxypropyl-β-cyclodextrin (HPbCD) to cats with NPC disease ameliorated hepatic disease, but doses sufficient to reduce neurological disease resulted in pulmonary toxicity. However, direct administration of HPβCD into the cisterna magna of presymptomatic cats with NPC disease prevented the onset of cerebellar dysfunction for greater than a year and resulted in a reduction in Purkinje cell loss and near-normal concentrations of cholesterol and sphingolipids. Moreover, administration of intracisternal HPβCD to NPC cats with ongoing cerebellar dysfunction slowed disease progression, increased survival time, and decreased the accumulation of brain gangliosides. An increase in hearing threshold was identified as a potential adverse effect. These studies in a feline animal model have provided critical data on efficacy and safety of drug administration directly into the central nervous system that will be important for advancing HPβCD into clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84923923825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923923825&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3010101

DO - 10.1126/scitranslmed.3010101

M3 - Article

C2 - 25717099

AN - SCOPUS:84923923825

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 276

M1 - 276ra26

ER -